Literature DB >> 19001055

The oxidized phospholipids linked to human apolipoprotein(a) do not derive from circulating low-density lipoproteins and are probably of cellular origin.

Celina Edelstein1, Binu Philips, Ditta Pfaffinger, Angelo M Scanu.   

Abstract

Lipoprotein (a) [Lp(a)], a cardiovascular risk factor, is a low-density lipoprotein (LDL) variant shown to bind to oxidized phospholipids (oxPLs); however, its binding mode and origin have not been clearly established. We isolated both LDL and Lp(a) from the plasma of a population of high-Lp(a) subjects and in each Lp(a) particle separated apolipoprotein(a) [apo(a)], from the LDL component, Lp(a(-)). These products were assayed by an ELISA using monoclonal antibody T15 with a known specificity for oxPLs. In each subject, the T15 reactivity was confined to apo(a). Moreover, the amount of oxPL bound to apo(a) was unaffected by plasma Lp(a) levels and apo(a) size polymorphism. We have previously shown that kringle V (KV) is the site of oxPL linkage in human apo(a). In this work, we expressed in human embryonic kidney cells a KV-containing recombinant that, when purified from the medium, contained oxPLs. In summary, in human plasma Lp(a), the oxPLs are located in apo(a) and not in the circulating LDLs, suggesting a cellular origin. This latter concept is supported by the studies in which an expressed KV-containing apo(a) microdomain exhibited oxPL reactivity. Thus, apo(a) can undergo potentially pathogenic posttranslational modifications in a cellular environment able to generate oxPL.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19001055      PMCID: PMC2653991          DOI: 10.1096/fj.08-122002

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  20 in total

Review 1.  Dominant role of the C-terminal domain in the binding of apolipoprotein(a) to the protein core of proteoglycans and other members of the vascular matrix.

Authors:  A M Scanu; C Edelstein; O Klezovitch
Journal:  Trends Cardiovasc Med       Date:  1999-10       Impact factor: 6.677

2.  A role for oxidized phospholipids in atherosclerosis.

Authors:  Judith A Berliner; Andrew D Watson
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

3.  High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins.

Authors:  Matthias Schneider; Joseph L Witztum; Stephen G Young; Erwin H Ludwig; Elizabeth R Miller; Sotirios Tsimikas; Linda K Curtiss; Santica M Marcovina; John M Taylor; Richard M Lawn; Thomas L Innerarity; Robert E Pitas
Journal:  J Lipid Res       Date:  2005-01-16       Impact factor: 5.922

4.  Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation.

Authors:  Peter Friedman; Sohvi Horkko; Daniel Steinberg; Joseph L Witztum; Edward A Dennis
Journal:  J Biol Chem       Date:  2001-12-14       Impact factor: 5.157

5.  Stimulation of interleukin-8 production in human THP-1 macrophages by apolipoprotein(a). Evidence for a critical involvement of elements in its C-terminal domain.

Authors:  O Klezovitch; C Edelstein; A M Scanu
Journal:  J Biol Chem       Date:  2001-10-08       Impact factor: 5.157

6.  Functional and metabolic differences between elastase-generated fragments of human lipoprotein[a] and apolipoprotein[a].

Authors:  C Edelstein; J A Italia; O Klezovitch; A M Scanu
Journal:  J Lipid Res       Date:  1996-08       Impact factor: 5.922

7.  Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity.

Authors:  P X Shaw; S Hörkkö; M K Chang; L K Curtiss; W Palinski; G J Silverman; J L Witztum
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

8.  Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes.

Authors:  Sotirios Tsimikas; Claes Bergmark; Reinaldo W Beyer; Raj Patel; Jennifer Pattison; Elizabeth Miller; Joseph Juliano; Joseph L Witztum
Journal:  J Am Coll Cardiol       Date:  2003-02-05       Impact factor: 24.094

Review 9.  Lipoprotein(a) and the atherothrombotic process: mechanistic insights and clinical implications.

Authors:  Angelo M Scanu
Journal:  Curr Atheroscler Rep       Date:  2003-03       Impact factor: 5.113

10.  A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.

Authors:  Claes Bergmark; Asheesh Dewan; Alexina Orsoni; Esther Merki; Elizabeth R Miller; Min-Jeong Shin; Christoph J Binder; Sohvi Hörkkö; Ronald M Krauss; M John Chapman; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2008-07-01       Impact factor: 5.922

View more
  5 in total

1.  Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet.

Authors:  Nastaran Faghihnia; Sotirios Tsimikas; Elizabeth R Miller; Joseph L Witztum; Ronald M Krauss
Journal:  J Lipid Res       Date:  2010-08-16       Impact factor: 5.922

2.  Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts.

Authors:  Celina Edelstein; Ditta Pfaffinger; Ming Yang; John S Hill; Angelo M Scanu
Journal:  Biochim Biophys Acta       Date:  2010-03-24

3.  Lipoprotein(a): Cellular Effects and Molecular Mechanisms.

Authors:  Kirsten Riches; Karen E Porter
Journal:  Cholesterol       Date:  2012-09-06

4.  Mouse plasminogen has oxidized phosphatidylcholine adducts that are not metabolized by lipoprotein-associated phospholipase A₂under basal conditions.

Authors:  Celina Edelstein; Ditta Pfaffinger; Ethan C Reichert; Diana M Stafforini; Angelo M Scanu
Journal:  Int J Mol Sci       Date:  2010-12-22       Impact factor: 5.923

Review 5.  Lipoprotein(a) the Insurgent: A New Insight into the Structure, Function, Metabolism, Pathogenicity, and Medications Affecting Lipoprotein(a) Molecule.

Authors:  Motasim M Jawi; Jiri Frohlich; Sammy Y Chan
Journal:  J Lipids       Date:  2020-02-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.